Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial by Goldberg, Sarah B, MD, Schalper, Kurt A, MD, Gettinger, Scott N, Prof, Mahajan, Amit, MD, Herbst, Roy S, Prof, Chiang, Anne C, MD, Lilenbaum, Rogerio, Prof, Wilson, Frederick H, MD, Omay, Sacit Bulent, MD, Yu, James B, Prof, Jilaveanu, Lucia, PhD, Tran, Thuy, MD, Pavlik, Kira, MPH, Rowen, Elin, MSN, Gerrish, Heather, BSN, Komlo, Annette, MBA, Gupta, Richa, BS, Wyatt, Hailey, BS, Ribeiro, Matthew, BS, Kluger, Yuval, Prof, Zhou, Geyu, BSc, Wei, Wei, PhD, Chiang, Veronica L, Prof, Kluger, Harriet M, Prof

Get full text